SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: which are the benefits?

Journal Title: Revista de Medicină Militară - Year 2019, Vol 0, Issue 1

Abstract

Two major trials, EMPA-REG OUTCOME trial (with Empagliflozin) and CANVAS trial (with Canagliflozin) have demonstrated the beneficial effects of SGLT2 inhibitors in patients with type 2 diabetes at risk for heart failure. SGLT2 inhibitors possess a unique pharmacological profile and have shown a significant reduction of hospitalization for heart failure in diabetic patients, immediately after treatment commencement. It seems that their effects are beneficial both in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. SGLT2 inhibitors reduce cardiovascular endpoints in patients with diabetes and high cardiovascular risk, most likely through a reduction of heart failure-related events. Empagliflozin treatment exerts beneficial effects on vascular function and central haemodynamics. Various mechanisms seem to contribute to the beneficial effects of SGLT2 inhibitors in heart failure. Taking into consideration their cardiovascular benefits and the number of ongoing trials with these drugs, there is a possibility to expand their indication to nondiabetic patients with heart failure. This review focuses on the newest insights into the beneficial effects of SGLT2 inhibitors on the cardiovascular system

Authors and Affiliations

Camelia Diaconu, Teodor Salmen, Mihnea A Gaman, Ovidiu Bratu, Dan Mischianu, D Marcu, Andra I Suceveanu, Raluca S. Costache, Anca Pantea Stoian

Keywords

Related Articles

Efficacy and safety of Ombitasvir/Paritaprevir/Ritonavir+ Dasabuvir and Ribavirin in patients with compensated HCV cirrhosis

Background and aim: Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir in association with ribavirin was the only interferon-free regimen available in 2015 in Romania for compensated HCV cirrhosis. The aim of our study is to re...

Association of rare disease and acute intoxication – case report

Benzodiazepine overdose has various clinical manifestation, mainly regarding the central nervous system (CNS), cardiac and respiratory side effects, but rarely results in significant morbidity and mortality. Acute benzod...

General considerations regarding the infections with the Escherichia coli pathogen

Escherichia coli is the species of the genus Escherichia with the greatest epidemiological impact. Escherichia coli infections are found mainly in places with poor hygiene; the infants with ages between 1 and 3 years old...

Improved methodology of using simulators develops better practical skills in laparoscopy of future residents

Background and aim: Minimally invasive surgery represents the actual tendency in many medical domains including urology. Gaining practical skills for these procedures becomes essential when preparing the future resident...

Gingival involvement of oral non-tumoral mucosal diseases

Gingival conditions are frequently encountered in dental clinical practice and they can raise diagnosis and treatment problems. The diagnostic is variable from normal conditions to autoimmune diseases or even malignancy....

Download PDF file
  • EP ID EP481269
  • DOI -
  • Views 75
  • Downloads 0

How To Cite

Camelia Diaconu, Teodor Salmen, Mihnea A Gaman, Ovidiu Bratu, Dan Mischianu, D Marcu, Andra I Suceveanu, Raluca S. Costache, Anca Pantea Stoian (2019). SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: which are the benefits?. Revista de Medicină Militară, 0(1), 16-21. https://europub.co.uk/articles/-A-481269